YIDU TECH (02158), a leading AI-driven healthcare company listed on the Hong Kong Stock Exchange, announced on August 10 that its affiliate, Yiduyun (Beijing) Technology Co., Ltd., has successfully won a bid for the信息化配套建设 (information technology supporting infrastructure) project at the Tongzhou campus of the Capital Institute of Pediatrics-affiliated Capital Children's Medical Center. The total contract value is approximately RMB 8.6 million.

This successful bid represents a landmark project secured by YIDU TECH in the Beijing public tertiary smart hospital sector after achieving profitability in its fiscal year 2026. It further validates the company's ability to deliver its AI Hospital solutions to top-tier public hospitals. The Tongzhou campus project is a key initiative under Beijing's overall urban planning, aimed at relieving non-capital functions and redistributing high-quality pediatric medical resources. It is designed to address the shortage of pediatric care in the city's sub-center and enhance the overall pediatric treatment standards in the surrounding areas. This year's Beijing government work report highlights the objective to "substantially complete the Capital Institute of Pediatrics' Tongzhou campus."

Industry observers note that this win not only secures YIDU TECH's role in a major healthcare expansion project but also opens a new application window for its medical data governance and AI capabilities in the high-barrier field of pediatric care. Pediatric medicine involves complex disease profiles, a wide age range, and high difficulty in data standardization, placing elevated demands on data governance, system coordination, and intelligent support for IT infrastructure. Participation in the Tongzhou campus's信息化配套建设 is expected to further demonstrate YIDU TECH's project implementation and technical service capabilities in complex clinical settings, while also expanding its coverage of public tertiary hospitals.

To date, YIDU TECH's AI healthcare solutions have been deployed in 133 top-tier tertiary hospitals nationwide, including renowned institutions such as Peking Union Medical College Hospital, Peking University Cancer Hospital, and Tsinghua Changgung Hospital. This latest contract comes at a historical inflection point for the company's fundamentals, with multiple positive catalysts supporting its order expansion strategy. On June 30, YIDU TECH reported its full-year results for fiscal year 2026 (ending March 31, 2026). The company achieved total revenue of RMB 820 million, a year-over-year increase of 14.6%, and a net profit of RMB 78.766 million, a significant turnaround from a loss of RMB 135 million in the prior fiscal year, substantially exceeding the upper end of its previous profit guidance.

The quality of profitability has also improved markedly. The overall gross margin rose to 36.4%, while adjusted EBITDA surged 462% year-over-year to RMB 220 million. Operating cash flow turned positive in the second half of the year, and the full-year net cash outflow from operating activities narrowed by 91.2% year-over-year, demonstrating a fully-formed commercial monetization capability. Beyond the strong financial results, the company has signaled a commitment to shareholder returns. The board has proposed its first-ever final dividend of HKD 0.04 per share, conveying confidence in long-term cash flow. Additionally, the company has continued its significant share buyback program, repurchasing a total of approximately 42.69 million shares during the fiscal year, underscoring the management's belief in the long-term value of its AI healthcare initiatives.